ZA200104130B - Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof. - Google Patents
Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof. Download PDFInfo
- Publication number
- ZA200104130B ZA200104130B ZA200104130A ZA200104130A ZA200104130B ZA 200104130 B ZA200104130 B ZA 200104130B ZA 200104130 A ZA200104130 A ZA 200104130A ZA 200104130 A ZA200104130 A ZA 200104130A ZA 200104130 B ZA200104130 B ZA 200104130B
- Authority
- ZA
- South Africa
- Prior art keywords
- lys
- gly
- compound
- asn
- amino acid
- Prior art date
Links
- 230000014399 negative regulation of angiogenesis Effects 0.000 title claims description 5
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 title description 157
- 108090000765 processed proteins & peptides Proteins 0.000 title description 72
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 55
- 210000002889 endothelial cell Anatomy 0.000 claims description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 230000033115 angiogenesis Effects 0.000 claims description 23
- 230000004663 cell proliferation Effects 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 125000006239 protecting group Chemical group 0.000 claims description 18
- 108010077861 Kininogens Proteins 0.000 claims description 15
- 102000010631 Kininogens Human genes 0.000 claims description 14
- 230000004528 endothelial cell apoptotic process Effects 0.000 claims description 9
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100035792 Kininogen-1 Human genes 0.000 description 167
- 210000004027 cell Anatomy 0.000 description 67
- 102000004196 processed proteins & peptides Human genes 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 45
- 229940024606 amino acid Drugs 0.000 description 44
- 230000035755 proliferation Effects 0.000 description 23
- 238000000034 method Methods 0.000 description 19
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 13
- 108010082117 matrigel Proteins 0.000 description 12
- -1 methoxysuccinyl Chemical group 0.000 description 12
- 101800004538 Bradykinin Proteins 0.000 description 11
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 11
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000001772 anti-angiogenic effect Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 7
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 7
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108090000113 Plasma Kallikrein Proteins 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010058188 Low-Molecular-Weight Kininogen Proteins 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 102000003827 Plasma Kallikrein Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000001399 Kallikrein Human genes 0.000 description 4
- 108060005987 Kallikrein Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108010031318 Vitronectin Proteins 0.000 description 3
- 102100035140 Vitronectin Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- VIBDVOOELVZGDU-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzene-1,3-dicarboximidamide Chemical compound NC(=N)C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 VIBDVOOELVZGDU-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000012936 Angiostatins Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102400001047 Endostatin Human genes 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108700005078 Synthetic Genes Chemical class 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102000007614 Thrombospondin 1 Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 108700005467 recombinant KCB-1 Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- MCYMLYCMBFUHBL-UHFFFAOYSA-N 4-(1h-indol-2-yl)benzene-1,3-dicarboximidamide;dihydrochloride Chemical compound Cl.Cl.NC(=N)C1=CC(C(=N)N)=CC=C1C1=CC2=CC=CC=C2N1 MCYMLYCMBFUHBL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- YIWFXZNIBQBFHR-LURJTMIESA-N Gly-His Chemical compound [NH3+]CC(=O)N[C@H](C([O-])=O)CC1=CN=CN1 YIWFXZNIBQBFHR-LURJTMIESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VLDVBZICYBVQHB-IUCAKERBSA-N His-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CN=CN1 VLDVBZICYBVQHB-IUCAKERBSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000000232 Merrifield's solid-phase procedure Methods 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- UXZMLECYBHANRH-UHFFFAOYSA-K [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F Chemical compound [B+3].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F UXZMLECYBHANRH-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Description
~ | tu w WO 00/27866 - PCT/US99/26419
INHIBITION OF ANGIOGENESIS BY HIGH MOLECULAR
WEIGHT KININOGEN AND PEPTIDE ANALOGS THEREOF
The benefit of U.S. provisional patent application 60/107,833 fled November 10, 1998 is hereby claimed. The entire disclosure of application 60/107,833 is incorporated herein by reference.
The invention relates to therapeutic compounds and methods for inhibiting angiogenesis. | Background of the Invention
Angiogenesis
Angiogenesis is the process in which new blood vessels grow ’ into an area which lacks a sufficient blood supply. Angiogenesis commences with the erosion of the basement membrane surrounding ‘ 15 endothelial cells and pericytes forming capillary blood vessels. Erosion of the basement membrane is triggered by enzymes released by endothelial cells and leukocytes. The endothelial cells then migrate through the eroded basement membrane when induced by angiogenic stimulants. The migrating cells form a “sprout” off the parent blood vessel. The migrating endothelial cells proliferate, and the sprouts merge to form capillary loops, thus forming a new blood vessel. N
Angiogenesis can occur under certain normal conditions in mammals such as in wound healing, in fetal and embryonic development, and in the formation of the corpus luteum, endometrium and placenta.
Angiogenesis also occurs in certain disease states such as in tumor os. So formation and expansion, or in the retina of patients with certain ocular ) disorders. Angiogenesis can also occur in a rheumatoid joint, hastening jointdestruction by allowing an influx of leukocytes with subsequent release of inflammatory mediators.
The evidence for the role of angiogenesis in tumor growth was extensively reviewed by O'Reilly and Folkman in U.S. Pat. 5,639,725, the entire disclosure of which is incorporated herein by reference. It is now generally accepted that the growth of tumors is critically dependent upon this process. Primary or metastatic tumor foci are unable to achieve a size of more than approximately 2 mm in the absence of neovascularization.
Serial evaluation of transgenic mice predisposed to develop neoplasms has demonstrated that neovascularization of premalignant lesions precedes their evolution into tumors (Folkman et al., Nature 339:58-61, 1989), and that inhibition of angiogenesis delays the growth of such lesions, as well as their assumption of a malignant phenotype (Hanahan et al., Cell 86:353- 364, 1996). In humans, several studies have demonstrated that increased density of microvessels within a tumor is associated with a poor clinical outcome (Weidner et al., J Natl Cancer Inst 84:1875-1887, 1992).
An emerging paradigm is that proteolytic fragments of plasma or extracellular matrix proteins regulate angiogenesis. To date, several polypeptides with such activities have been identified. These include angiostatin, which contains kringles 1-4 plasminogen (O'Reilly et al., Cell . 79:315-328, 1994), endostatin, a 20 kD C-terminal fragment of collagen
XVII (O'Reilly et al., Cell 88:277-285, 1997), PEX, the hemopexin domain of matrix metalloprotease 2 (Brooks et al., Cell 92:391-400, 1998), the C- ) tenitiai 16 RD frayrmeni of proiaciin (Clapp et ai., EndocHhol 133:1292- 1299, 1993) and a 29 kD fragment of fibronectin (Homandberg ef ai., Am
J Pathol 120:327-332, 1985). In addition, both intact thrombospondin 1 as well as peptides derived from its procollagen domain and properdin-like type-1 repeats express potent anti-angiogenic activity (Good et al., Proc
Nat Acad Sci USA 87:6624-6628, 1990); Tolsma et al., J Cell Biol 122:497- 511, 1993. In preclinical models, several of these fragments inhibited tumor growth, and some induced tumor regression and dormancy (Boehm et al., Nature 390:404-407, 1997).
La WO 00/27866 - PCT/US99/26419 -3- oo
High Molecular Weight Kininogen
High molecular weight kininogen (HK) is a 120 kD glycoprotein containing heavy and light chains, comprised of domains 1 through 3, and 5 and 6, respectively (Kaplan et al., Blood 70:1-15, 1987).
The heavy and light chains are linked by domain 4, which contains bradykinin, a nonapeptide which mediates several events including NO- dependent vasodilation (Weimer et al., J Pharm Exp Therapeutics 262:729- 733, 1992). HK (also referred to as "single chain high molecular weight kininogen") binds with high affinity to endothelial cells, where it is cleaved to two-chain high molecular weight kininogen (HK,) by plasma kallikrein.
Bradykinin is released from HK through cleavage mediated by plasma kallikrein (Kaplan et al., Blood 70:1-15, 1987). This event occurs on the surface of endothelial cells following the activation of prekallikrein to kallikrein by an endothelial cell protease (Motta et al., Blood 91:515-528, 1998). Cleavage of HK to form HK, and release bradykinin occurs between i Lys(362) and Arg(363). HK, contains a 62 kD heavy chain and a 56 kD : light chain linked by a disulfide bond. " : Conversion of HK to HK, is accompanied by a dramatic : structural rearrangement, which has been demonstrated using rotary shadowing electron microscopy (Weisel et al. J. Biol Chem 269:10100- 10106, 1994). HK,, but not HK, has been shown to inhibit the adhesion of : endothelial and other cell types to vitronectin (Asakura, J. Cell Biol 116:465-476, 1992).
Although the binding of HK to endothelial cells has been well . 25 characterized, comparatively little attention has been devoted to endothelial cell binding of HK, Furthermore, although binding of bradykinin to endothelial cells induces well-defined responses, functional consequences of the direct binding of HK, have not been reported.
The compounds of the present invention are in the form of peptides which possess anti-angiogenic activity.
In all embodiments; the peptide may optionally comprise an amino-terminal and/or carboxy-terminal protecting group.
A compound of the formula X,-His-Lys-X-Lys-X, (hereinafter “X,-His-Lys-X-Lys-X, peptide”) is provided wherein
X is any amino acid,
X,is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids, and
X, is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids.
Preferably, X is an amino acid having a nonpolar side chain, i.e., Ala, Leu, lle, Val, Pro, Phe, Trp, or Met; or X is an amino acid having a polar side group which is uncharged at pH 6.0 to 7.0, the zone of physiological pH, i.e., Ser, Thr, Tyr, Asn, Gin, Cys, or Gly. Most preferably,
X is Asn, Phe or His.
Preferred compounds comprise fragments of HK. In one group of such preferred compounds,
X, is (i) zero amino acids, or (ii) the segment His-Gly-His-Glu-GIn-
Gin-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1) , or N-terminal truncation fragment thereof containing at least one amino acid, and
X, is (i) zero amino acids, or ) (ii) the segment Leu-Asp-Asp-Asp-Lei-Gliu-His-
GIn-Gly-Gly-His-Val (SEQ ID NO:2) , or C-terminal truncation fragment thereof containing at least one amino acid.
In another group of such preferred compounds,
X, is (i) zero amino acids, or (if) the segment Gly-His-Lys-His-Lys-His-Gly-
His-Gly-His-Gly-Lys (SEQ ID NO:3) or N-terminal
¥ WO 00/27866 - PCT/US99/26419 _5. oo truncation fragment thereof containing at least one amino acid, and
X, is (i) zero amino acids, or (ii) the segment Gly-Lys-Lys-Asn-Gly-Lys-His-
Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4) or C-terminal truncation fragment thereof containing at least one amino acid. -
According to a further preferred embodiment of the invention, the compound has a substantial amino acid homology to either the amino : acid sequence His-Gly-His-Glu-GIn-Gin-His-Gly-Leu-Gly-His-Gly-His-Lys-
Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-Gly-His-Val (SEQ ID
NO:5), or the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-
His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-
Lys-Thr (SEQ ID NO:6).
Exemplary and preferred compounds include: (a) His-Gly-His-Glu-GIn-GIn-His-Gly-Leu-Gly-His-Gly-
His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-Gly-
His-Val (SEQ ID NO:5); (b) Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu- ’ His-Gin-Gly-Gly-His (SEQ ID NO:7); (c) Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys- . His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-
Lys-Thr (SEQ ID NO:6); (d) Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-
Gly-Lys-Lys-Asn (SEQ ID NO:8); and (e) His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-
Gly-Trp-Lys-Thr (SEQ ID NO:9).
The invention also encompasses a method of ‘inhibiting endothelial cell proliferation comprising contacting endothelial cells with HK,
HK, or a X,-His-Lys-X-Lys-X, peptide.
The invention also encompasses a method of inducing apoptosis of endothelial cells comprising contacting endothelial cells with
HK, HK, or a X;-His-Lys-X-Lys-X, peptide.
The invention is also a composition comprising a pharmaceutically effective carrier and HK, HK, or a X,-His-Lys-X-Lys-X, peptide.
The invention is also a method of inhibiting angiogenesis in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a composition comprising a pharmaceutically effective carrier and HK, HK, or a X,-His-Lys-X-Lys-X, peptide. The mammal treated is preferably a human being.
Other aspects and advantages of the present invention are described in the drawings and in the following detailed description of the preferred embodiments thereof.
Abbreviations and Short Forms
The following abbreviations and short forms are used in this specification. “bFGF” is recombinant human basic fibroblast growth factor. “HK” means the mature form of high molecular weight kininogen, and any allelic variations thereof. By “mature” is meant the post- : translationally-modified form of HK which results from cleavage of an eighteen amino acid leader from the initially translated molecule. Ali numbering with respect to amino acid positions of HK is from the N- terminus of the mature form as position 1. "HK" is synonymous with ) "single chain HK", the mafiiré form of Righ molecular weight Kininogen prior to cleavage by kallikrein and the formation of two-chain high molecular weight kininogen. “HK,” means two-chain high molecular weight kininogen, the product of kallikrein cleavage of mature high molecular weight kininogen, and any allelic variations thereof. . *“*HDMVEC” means human dermal microvascular endothelial cells. co "HGF" means hepatocyte growth factor. “HUVEC” means human umbilical vein endothelial cell of WO 00/27866 : PCT/US99/26419 “PDGF” is platelet-derived growth factor. “TGF-B” is transforming growth factor-p. “VEGF” means vascular endothelial cell growth factor. “X;-His-Lys-X-Lys-X, peptide” means a compound of the indicated formula wherein X, X, and X, are defined as above.
Amino Acid Abbreviations
The nomenclature used to describe polypeptide compounds of the present invention follows the conventional practice wherein the amino group is presented to the lest and the carboxy group to the right of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino-and carboxy-terminal groups, although not specifically shown, will be understood to be in the . form they would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by a one-letter or three-letter designation, corresponding to the trivial name of the amino acid, in accordance with the following schedule:
A Alanine Ala
Cc Cysteine Cys : D Aspartic Acid Asp
E Glutamic Acid Glu
F Phenylalanine Phe 3 G Glycine Gly
H Histidine His : | Isoleucine lle
K Lysine Lys
L Leucine Leu . M Methionine Met
N Asparagine Asn
P Proline Pro
Q Glutamine Gin
R Arginine Arg
S Serine Ser
T Threonine Thr \J Valine Val
WwW Tryptophan Trp
Y Tyrosine Tyr
Definitions oo
The following definitions, of terms used throughout the 40 specification, are intended as an aid to understanding the scope and practice of the present invention.
“Angiogenesis” means the generation of new blood vessels into a tissue or organ. “Apoptosis” means a process of programmed cell death.
A"peptide" is a compound comprised of amino acid residues covalently linked by peptide bonds.
The expression “amino acid” as used herein is meant to include both natural and synthetic amino acids, and both D and L amino acids. "Natural amino acid" means any of the twenty primary, naturally occurring amino acids which typically form peptides, polypeptides, and proteins. "Synthetic amino acid" means any otheramino acid, regardless of whether it is prepared synthetically or derived from a natural source. As used herein, "synthetic amino acid" also encompasses chemically modified amino acids, including but not limited to salts, derivatives (such as amides), and substitutions. Amino acids contained within the peptides of the present invention, and particularly at the carboxy- or amino-terminus, can be modified by methylation, amidation, acetylation or substitution with other chemical groups which can change the peptide’s circulating half life without adversely affecting their activity. Additionally, a disulfide linkage may be present or absent in the peptides of the invention, as long as anti- angiogenic activity is maintained.
Amino acids have the following general structure: , . coon
L.
Amino acids are classified into seven groups on the basis of the side chain
R: (1) aliphatic side chains, (2) side chains containing a hydroxylic (OH) group, (3) side chains containing sulfur atoms, (4) side chains containing an acidic or amide group, (5) side chains containing a basic group, (6) side chains containing an aromatic ring, and (7) proline, an imino acid in which the side chain is fused to the amino group. Peptides comprising a large number of amino acids are sometimes called "polypeptides". The amino acids of the peptides described herein and in the appended claims are
. . A of WO 00/27866 : oo PCT/US99/26419 - understood to be either D or L amino acids with L amino acids being preferred. "Homology" means similarity of sequence reflecting a common evolutionary origin. Peptides or proteins are said to have homology, or similarity, if a substantial number of their amino acids are either (1) identical, or (2) have a chemically similar R side chain. Nucleic : acids are said to have homology if a substantial number of their nucleotides are identical.
As used herein, “protected” with respect to a terminal amino group refers to a terminal amino group of a peptide, which terminal - amino group is coupled with any of various amino-terminal protecting - groups traditionally employed in peptide synthesis. Such protecting groups include, for example, acyl protecting groups such as formyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl; aromatic urethane protecting groups such as benzyloxycarbonyl; and aliphatic urethane protecting ; groups, for example, tert-butoxycarbonyl or adamantyloxycarbonyl. See
Gross and Mienhofer, eds., The Peptides, vol. 3, pp. 3-88 (Academic ~ Press, New York, 1981) for suitable protecting groups. ’ As used herein, “protected” with respect to a terminal carboxyl group refers to a terminal carboxyl group of a peptide, which 2 terminal carboxyl group is coupled with any of various carboxyl-terminal protecting groups. Such protecting groups include, for example, tert-butyl, : benzyl or other acceptable groups linked to the terminal carboxyl group through an ester or ether bond. . 25 "Substantial amino acid sequence homology" means an amino acid sequence homology greater than about 30 %, preferably greater than about 60%, more preferably greater than about 80%, and most preferably greater than about 90 %.
By “N-terminal truncation fragment” with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the N-terminus thereof. .
By “C-terminal truncation fragment” with respect to an amino acid sequence is meant a fragment obtained from a parent sequence by removing one or more amino acids from the C-terminus : thereof.
Fig. 1 shows the inhibition of endothelial cell proliferation over time following contact with HK.
Fig. 2 shows the concentration-dependent inhibition of endothelial cell proliferation by HK, (fine crosshatched bars), HK (white bars) and low molecular weight kininogen (coarse crosshatched bars).
Low molecular weight kininogen is non-inhibitory.
Fig. 3 shows the ability of 30 nM HK, to inhibit endothelial cell proliferation stimulated by a variety of growth factors.
Fig. 4 shows that HK, inhibits proliferation of two types of endothelial cells (HUVEC and HDMVEC), but not human aortic smooth muscle cells (HASMC).
Fig. 5 shows the inhibition of endothelial cell proliferation as a function of HK, concentration and cell density in the culture. White bars = 1,500 cells/well; coarse crosshatched bars = 3,000 cells/well; fine crosshatched bars = 6,000 cells/well; very fine crosshatched bars = 12,000 cells/well; vertically hatched bars = 24,000 cells/well.
Fig. 6A shows endothelial cells after staining with 4',6’-diamidino-2-phenylindole hydrochloride. Fig. 6B shows endothelial cells upon staining with 4',6’-diamidino-2-phenylindole hydrochloride after four hours of exposure to HK.
Figs. 7A and 7B show DNA fragmentation in endothelial cells exposed to HK, as a function of time (at 30 nM concentration) and concentration (at 12 hours), respectively.
Figs. 8A and 8B show athymic Ncr nude mice injected subcutaneously with chilled Matrigel® containing bFGF which resulted in formation of a visible “plug”. The plug was photographed four days post implantation. Figs. 8C and 8D are similar to 8A and 8B except that the plug contained HK.. The arrows in the figures point to the plug periphery.
Plug vascularization is visible in Figs. 8A and 8B, but absent in Figs. 8C and 8D.
Amended Sheet 16/05/2002 to WO 00/27866 PCT/US99/26419
The present invention is based upon the discovery that HK, and peptide analogs of certain sites in the HK domain 5 inhibit endothelial cell proliferation and/or induce endothelial cell apoptosis. These activities confer upon HK, and the X,-His-Lys-X-Lys-X, peptides the ability to inhibit cytokine-driven angiogenesis in vivo.
Antiproliferative effects are observed at concentrations below 1.0 nM. The use among different iaboratories of endothelial cells of different origin, and/or varying concentrations of endothelial cell growth factors, makes a direct comparison of the relative potency of HK, and previously-reported anti-angiogenic polypeptides difficult. However, the observations made herein suggest that the in vitro potency of HK, in this regard is similar to that of angiostatin (O'Reilly et al., Cell 79:315-328, 1994), endostatin (O'Reilly et al., Cell 88:277-285, 1997) and TSP-1 (Good et al., Proc Nat Acad Sci USA 87.:6624-6628, 1990). Furthermore, when the plasma concentration (670 nM) of the parent molecule, HK, is considered, it is apparent that the anti-angiogenic activity of HK, and the
X,-His-Lys-X-Lys-X, peptides is physiologically significant.
The effects of HK,, and thus the effects of the X,-His-Lys-X-
Lys-X, peptides also, are cell specific. No inhibition of the proliferation of either human aortic smooth muscle cells or HEK 293 cells by HK, is observed. According to the assays utilized herein, HK, potently inhibits the proliferation of human umbilical vein and microvascular endothelial cells in vitro in response to various pro-angiogenic growth factors: bFGF, VEGF, hepatocyte growth factor, TGF-f8 and PDGF. Inhibition of endotheliai cell : 25 proliferation is detected within 6 hours of exposure of the cells to HK, and is accompanied by morphologic and biochemical evidence of cell apoptosis.
Furthermore, as shown herein, HK, is effective in an in vivo model of angiogenesis. HK, inhibits the ingrowth of new blood vessels into a reconstituted extracellular matrix (Matrigel) containing the pro-angiogenic growth factor bFGF implanted subcutaneously into mice.
Without wishing to be bound by any theory, the observation that HK,, but not single chain HK, inhibits endothelial cell proliferation suggests that the structural change which the molecule undergoes following kallikrein-mediated cleavage is important for expression of its anti- angiogenic activity.
The mature human HK amino acid sequence is set forth in the recent review by Colman and Schmaier, Blood, 90:3819-3843 (1997), for example. HK, generated by plasma kallikrein cleavage of HK differs from HK in that it lacks the nine amino acid segment comprising HK amino acids 363-371. This segment is released from HK as the nonapeptide bradykinin. The two chains of HK resulting from the elimination of bradykinin remain linked by a disulfide bond between cysteine residues at positions 10 and 656 of mature HK. The N-terminal and C-terminal chains of HK, generated by plasma kallikrein cleavage of HK and release of bradykinin are known as HK “heavy” and “light” chains, respectively. HK, may be generated by treating HK with plasma kallikrein, according to well- known methods. HK, is also commercially available. Furthermore, other enzymes, such as plasmin, chymotrypsin or matrix metalloproteases, for example, may degrade HK to release peptides similar to those described herein.
HK domain 5 spans HK residues 384-502. Located within domain 5 are two separate segments characterized by the sequence His-
Lys-X-Lys. The first such segment occurs at position 457-460. The second segment occurs at position 488-491. HK, derived peptides containing the His-Lys-X-Lys sequence inhibit endothelial cell proliferation and are useful as anti-angiogenic agents.
The X,-His-Lys-X-Lys-X, peptides of the present invention may be recombinant peptides, natural peptides, or synthetic peptides. :
Tiley may aisu Ue ui einically synthesized, using, for example; solid phase synthesis methods.
In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which the constituent amino acids are added to the growing peptide chain in the desired sequence. The use of various N-protecting groups, e.g., the carbobenzyloxy group or the t-butyloxycarbony! group, various coupling reagents (e.g., dicyclohexylcarbodiimide or carbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy- succinimide, and the various cleavage reagents, e.g., trifluoroacetic acid
< WO 0027866 : PCT/US99/26419 (TFA), HCl in dioxane, boron tris-(trifluoracetate) and cyanogen bromide, ) and reaction in solution with isolation and purification of intermediates is well-known classical peptide methodology. The preferred peptide synthesis method follows conventional Merrifield solid-phase procedures. See
Merrifield, J. Amer. Chem. Soc. 85:2149-54 (1963) and Science 50:178-85 (1965). Additional information about the solid phase synthesis procedure can be had by reference to the treatise by Steward and Young (Solid
Phase Peptide Synthesis, W.H. Freeman & Co., San Francisco, 1969, and the review chapter by Merrifield in Advances in Enzymology 32:221-296,
F.F. Nold, Ed., Interscience Publishers, New York, 1969; and Erickson and
Merrifield, The Proteins 2:255 et seq. (ed. Neurath and Hill), Academic
Press, New York, 1976. The synthesis of peptides by solution methods is described in Neurath et al., eds. (The Proteins, Vol. ll, 3d Ed., Academic
Press, NY (1976)).
Crude peptides may be purified using preparative high performance liquid chromatography. The amino terminus may be blocked according, for example, to the methods described by Yang et al. (FEBS
Lett. 272:61-64 (1990)).
Peptide synthesis includes both manual and automated techniques employing commercially available peptide synthesizers. The
X,-His-Lys-X-Lys-X, peptides may be prepared by chemical synthesis and i biological activity can be tested using the methods disclosed herein.
Alternatively, the X,-His-Lys-X-Lys-X, peptides may be prepared utilizing recombinant DNA technology, which comprises ’ 25 combining a nucleic acid encoding the peptide thereof in a suitable vector, inserting the resulting vector into a suitable host cell, recovering the peptide produced by the resulting host cell, and purifying the polypeptide recovered. The techniques of recombinant DNA technology are known to those of ordinary skill in the art. General methods for the cloning and expression of recombinant molecules are described in Maniatis (Molecular
Cloning, Cold Spring Harbor Laboratories, 1982), and in Sambrook (Molecular Cloning, Cold Spring Harbor Laboratories, Second Ed., 1989), and in Ausubel (Current Protocols iri Molecular Biology, Wiley and Sons, 1987), which are incorporated by reference. The complete cDNA of human
HK is reported, for example, by Takagi et al., J. Biol. Chem. 260:8601-8609
(1985), the entire disclosure of which is incorporated herein by reference. )
From this nucleic acid sequence, synthetic genes encoding HK,-derived peptides may be synthesized directly on a DNA synthesizer, or may be synthesized as complementary oligonucleotides which are ligated together to form the synthetic gene.
The nucleic acids encoding HK,-derived peptides may be operatively linked to one or more regulatory regions. Regulatory regions include promoters, polyadenylation signals, translation initiation signals (Kozak regions), termination codons, peptide cleavage sites, and enhancers. The regulatory sequences used must be functional within the cells of the vertebrate to be immunized. Selection of the appropriate regulatory region or regions is a routine matter, within the leve! of ordinary skill in the art.
Promoters that may be used in the present invention include both constitutive promoters and regulated (inducible) promoters. The promoters may be prokaryotic or eukaryotic depending on the host. Among the prokaryotic (including bacteriophage) promoters useful for practice of this invention are lacl, lacZ, T3, T7, lambda Pr’ PI’ and trp promoters.
Among the eukaryotic (including viral) promoters useful for practice of this invention are ubiquitous promoters (e.g. HPRT, vimentin, actin, tubulin), intermediate filament promoters (e.g. desmin, neurofilaments, keratin,
GFAP), therapeutic gene promoters (e.g. MDR type, CFTR, factor Vill), i tissue-specific promoters (e.g. actin promoter in smooth muscie cells), promoters which respond to a stimulus (e.g. steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, : cytortiegdiovirus immediate-gdriy, retrovirdl LTR, metallothionein, Sv-4u,
Eta, and MLP promoters. Tetracycline-regulated transcriptional modulators and CMV promoters are described in WO 96/01313, US 5,168,062 and 5,385,839, the entire disclosures of which are incorporated herein by reference.
Examples of polyadenylation signals that can be used in the present invention include but are not limited to SV40 polyadenylation : signals and LTR polyadenylation signals.
of WO 00/27866 PCT/US99/26419
The X,-His-Lys-X-Lys-X, peptides prepared by either chemical synthesis or recombinant DNA technology may then be assayed for biological activity according to the assay methods described herein.
In some embodiments, the peptides of the present invention may be used in the form of a pharmaceutically acceptable salt.
Suitable acids which are capable of forming salts with the peptides include inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid; succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.
Suitable bases capable of forming salts with the peptides include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol- amines (e.g., ethanolamine, diethanolamine and the like).
The present invention provides methods for inhibiting angiogenesis. A preferred embodiment is a method of inhibiting the proliferation of endothelial cells, or obtaining apoptosis of such cells.
Accordingly, HK, HK, and/or one or more X-His-Lys-X-Lys-X, peptides is administered to a patient in need of such treatment. A therapeutically effective amount of the drug may be administered as a composition in . 25 combination with a pharmaceutically carrier. Although HK is considerably less anti-angiogenic than HK, it is possible that upon administration HK will be converted to HK,, and may therefore serve as a prodrug for HK,. In particular, it is believed that HK may be rapidly converted to HK, in tumors, or further cleaved by tumor-derived enzymes to release peptides the same or similar to the peptides disclosed herein.
The ability of HK, to inhibit the proliferation of endothelial cells cultured on different extracellular matrix (ECM) proteins was determined.
HK, (10nM) potently inhibited the proliferation of HUVEC cultured on gelatin, laminin and Matrigel, though slightly less potent inhibition, largely overcome by high concentrations of HK, (50 nM), occurred when cell were cultured on fibronectin or vitronectin. Intermediate effects were observed when cells were cultured on fibrinogen, though cells cultured on collagen types | or IV were resistant to the antiproliferative activity of HK,. In keeping with the results of proliferation assays, HK, caused apoptosis of endothelial cells cultured on gelatin, but not on collagen, and of cells cultured at low density, but not under confluent or near-confluent conditions. Without wishing to be bound by any theory, it appears that mature endothelial cells residing on an intact, collagen-rich basement membrane may be protected from HK, -induced apoptosis, and that HK, might selectively target angiogenic endothelial cells in a protease-rich tumor milieu in which ECM is partially degraded.
Pharmaceutically acceptable carriers include physiologically tolerable or acceptable diluents, excipients, solvents, adjuvants, or vehicles, for parenteral injection, for intranasal or sublingual delivery, for oral administration, for rectal or topical administration or the like. The compositions are preferably sterile and nonpyrogenic. Examples of suitable carriers include but are not limited to water, saline, dextrose, mannitol, lactose, or other sugars, lecithin, albumin, sodium glutamate cysteine hydrochloride, ethanol, polyols (propyleneglycol, ethylene, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, ethoxylated isosteraryl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
The pharmaceutical compositions may also contain minor . aimounis of nonioxic auxiiary substanses sueh as waking agents, emulsifying agents, pH buffering agents, antibacterial and antifungal agents (such as parabens, chlorobutanoi, phenol, sorbic acid, and the like). If desired, absorption enhancing or delaying agents (such as liposomes, aluminum monostearate, or gelatin) may be used. The compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. To
The compositions may be administered by any convenient route which will result in delivery to the site of undesired angiogenesis in an
04 WO 00/27866 : PCT/US99/26419 ~ amount effective for inhibiting that angiogenesis from proceeding. Modes of administration include, for example, orally, rectally, parenterally (intravenously, intramuscularly, intraarterially, or subcutaneously), intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray or aerosol. The compositions can also be delivered through a catheter for local delivery at a target site, or via a biodegradable polymer. The compositions may also be complexed to ligands, or antibodies, for targeted delivery of the compositions.
The compositions "are most effectively administered parenterally, preferably intravenously or subcutaneously. For intravenous administration, they may be dissolved in any appropriate intravenous delivery vehicle containing physiologically compatible substances, such as sodium chloride, glycine, and the like, having a buffered pH compatible with physiologic conditions. Such intravenous delivery vehicles are known to those skilled in the art. In a preferred embodiment, the vehicle is a sterile saline solution. If the peptides are sufficiently small (e.g., less than about 8-10 amino acids) other preferred routes of administration are intranasal, sublingual, and the like. Intravenous or subcutaneous administration may comprise, for example, injection or infusion.
The compositions according to the invention can be administered in any circumstance in which inhibition of angiogenesis is ] desired. Disease states which may be treated include but are not limited to cancer, rheumatoid arthritis, and certain ocular disorders characterized by undesired vascularization of the retina. Because the peptides of the ’ 25 invention are anti-angiogenic, cancers characterized by the growth of solid tumors through angiogenesis of the tissue surrounding the tumor site may be treated according to the invention.
The amount of active agent administered depends upon the degree of the anti-angiogenic effect desired. Those skilled in the art will derive appropriate dosages and schedules of administration to suit the specific circumstances and needs of the patient. Typically, dosages are from about 0.1 to about 100, preferably from about 0.5 to about 50, most preferably from about 1 to about 20, mg/kg of body weight. The active agent may be administered by injection daily, over a course of therapy lasting two to three weeks, for example. Alternatively, the agent may be administered by continuous infusion, such as via an implanted subcutaneous pump.
Peptides which inhibit endothelial cell proliferation by at least 30%, more preferably by at least 50%, most preferably by at least 70%, when incubated with such cells at a concentration of 50uM are preferred.
For purposes of this preference, percent inhibition of proliferation is determined according to the procedure and formula set forth in Example 1, part A, below.
The present invention is illustrated by the following non- limiting examples.
Materials
The materials utilized in the Examples were sourced as follows. Tissue culture medium and reagents were obtained from 15. Mediatech (Herndon, VA). Fetal bovine serum was from Hyclone (Logan,
Utah). Endothelial growth supplement was purified from bovine hypothalamii, as previously described (Maciag et al., Proc natl Acad Sci 76:5674-5678, 1979). Recombinant human basic fibroblast growth factor (bFGF), vascular endothelial cell growth factor (VEGF) and hepatocyte growth factor (HGF) were obtained from Collaborative Biomedical
Products/Becton Dickinson (Bedford, MA). Platelet-derived growth factor (PDGF) and transforming growth factor 3 (TGF -f) were from R&D Systems (Minneapolis, MN). Gelatin was purchased from Sigma (St. Louis, MO). :
Single arid two-chain High riciscular Weight Rininogen were obtained from
Enzyme Research Labs (South Bend, iN). HK, was >98% two-chain, as determined using 10% SDS-PAGE after reduction. Low molecular weight kininogen was purchased from American Research Products, (Beimont,
MA). Bradykinin was from Peninsula Laboratories (Belmont, CA), and rabbit anti-bradykinin antiserum from Sigma. AllHK, preparations used in these studies contained less than <0.01 EU/ml of endotoxin, as determined using the E-Toxate (Limulus Amoebocyte) assay (Sigma).
Synthetic Peptides
4 WO 00/27866 PCT/US99/26419 ~
Synthetic: peptides were synthesized on a Rainin Symphony multiple peptide synthesizer, using Fmoc chemistry. All resins (AnaSpec) used for solid phase synthesis were Wang resins preloaded with the first : amino acid. Fmoc amino acids were purchased from Perseptive
Biosystems, with side chain protective groups as follows: trityl (Asn, Cys,
Gln, and His), Boc (Lys and Trp), Ombu (Asp and Glu), T.U. (Ser, Thrand
Tyr) and P.G. (Arg). Deprotection of the Fmoc group was performed in piperidine in dimethtylformamide (DMF). Coupling was carried out done in
HBTU in N-methylmorpholine/DMF as the activator. Standard synthesis cycles were 3 x 30" washes with DMF, 3 x 15" deprotection with piperidine, 6 x 20" DMF washes, 45 minute coupling with amino acid and activator followed by 3 x 30" DMF washes.
Peptides were cleaved off the solid phase support with cleavage cocktail consisting of 88:5:5:2 (TFA:water:phenol: triisopropylsilane). Cleavage was done on the synthesizer. Peptides were precipitated with ether, pelleted by centrifugation, washed three times with ether and then allowed to dry. HPLC was carried out on a Beckman HPLC system using Rainin Dynamax Reversed Phase columns and an acetonitrile gradient in water. The desired peptide was detected during elution by off line MALDI-TOF mass spectrophotometry using a Perseptive
Biosystems Voyager instrument. Purified peptides were lyophilized and } then reanalyzed by MALDI-TOF mass spectrophotemetry.
Cell Culture Methods ’ The basic cell culture methods of the Examples are described as follows. Human umbilical vein endothelial cells (HUVEC) and human aortic smooth muscle cells were isolated and cultured as previously described (Graham et al, Blood 91:3300-7 1998). Human dermal microvascular endothelial cells (HDMVEC) were obtained from Clonetics (San Diego, CA) and cultured under identical conditions. All cells in these studies were of passage 3 or lower. N
Example 1
Effect of Single-Chain and Two-Chain High Molecular Weight
Kininogen on Endothelial Cell Proliferation :
A Experimental ~ To assess the effect of HK, on endothelial cell proliferation, cells were suspended at a concentration of 30,000 cells/ml in Medium 199 (M199) containing 2% FCS. One hundred microliters of this suspension was then plated in individual wells of a 96 well microplate precoated with 1% gelatin. After incubation for 2 hours, at 37°C, to allow cells to adhere and spread, medium was removed and replaced with fresh M199 containing (i) 2% FCS, (ii) 10 uM ZnCl, (iii) 10 ng/ml bFGF, VEGF, HGF,
TGF-B or PDGF and (iv) 50 uM HK or HK,. Cells were then incubated for 48 hours at 37°C, at which time the relative numbers of cells in each well : were determined using the Cell Titer® AQueous cell proliferation assay (Promega, Madison, WI). Briefly, 20 ul of a 19:1 (V/V) mixture of (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethylphenyl)-2-(4-sulfophenyl)-2
H-tetrazolium (MTS) and phenazine methosulfate (PMS) was added to each well, and after an additional hour of incubation, As, was measured using a BioRad model EL311 microplate reader. The percent inhibition of cell proliferation by HK, was determined using the formula: % inhibition = (1 - [(A4g0 (+cF, Ha) - Aaso (er) / (Auso sar) - Ago (-om)]) x 100, where (+GF) and (-GF) represent proliferation in the presence or absence of added growth factor, and (+GF, HK, ) represents proliferation in the presence of both growth factor and HK,. The significance of differences in relative endothelial cell proliferation cell numbers at the end of the proliferation assays was determined using the Student's two-tailed T-test for paired samples.
B. Results
Inhibition of endothelial cell proliferation by HK, was apparent within 6 hours after its addition to cells, at which time cell spreading appeared to be diminished, and the cells began to display a more rounded morphology. However, the extent to which proliferation was inhibited
Amended Sheet 16/05/2002
4 WO 00727866 PCT/US99/26419 increased progressively with longer exposure of cells to HK, (Figure 1).
Inhibition of endothelial cell proliferation by HK, occurred in a concentration-dependent manner; modest inhibition (14%) of bFGF (10 ng/ml) - stimulated proliferation occurred at an HK, concentration of <1.0 nM, while HK, inhibited proliferation by 50% at a concentration of approximately 8 nM (Figure 2).
Single-chain HK, low molecular weight kininogen and bradykinin were tested in the same manner. HK, inhibited endothelial cell proliferation to a much greater extent than single-chain HK. Low molecular weight kininogen, which is derived from alterative splicing ofthe kininogen gene and contains the entire HK light chain, domain 4 and a truncated domain 5 containing only 12 amino acids, had no effect on endothelial cell : proliferation (Figure 2). Finally, bradykinin did not inhibit proliferation, and anti-bradykinin antibodies did not inhibit the anti-proliferative effect of HK, (not shown). The latter results exclude the possibility that contamination of HK, with trace amounts of bradykinin was responsible for its ability to inhibit endothelial cell proliferation. Single-chain HK modestly inhibited endothelial cell proliferation.
These results demonstrate that HK, is a potent and rapid inhibitor of endothelial cell proliferation in vitro, and that these activities occur within a concentration range similar to that of previously-described i anti-angiogenic polypeptides.
HK, inhibited the proliferation of human endothelial cells in response to a number of mitogens, including bFGF, VEGF, HGF, TGF-B and PDGF, equally well (Figure 3). The mitogenic activity of each of these : factors is mediated through interactions with distinct receptors. Thus, without wishing to be bound by any theory, these results imply that the mechanism(s) by which HK, and the HK, peptides inhibits endothelial cell proliferation is unlikely to depend upon inhibition of growth factor binding.
HK, inhibited the proliferation of HUVEC and HDMVEC with similar potency but did not affect the proliferation of human aortic smooth muscle cells (Fig. 4) or HEK 293 cells (not shown), demonstrating that
HK,'s anti-proliferative effects were endothelial cell-specific. Furthermore, the ability of HK, to inhibit endothelial cell proliferation was inversely proportional to the density of the cell culture (Figure 5), suggesting that its effects may be at least partially dependent upon the rate of cell proliferation and DNA synthesis.
In other experiments, the ability of HK, to inhibit the proliferation of endothelial cells cultured on different extracellular matrix (ECM) proteins. HK, (10nM) potently inhibited the proliferation of HUVEC cultured on gelatin, laminin and Matrigel, though slightly less potent inhibition, largely overcome by high concentrations of HK, (50 nM), occurred when cells were cultured on fibronectin or vitronectin.
Intermediate effects were observed when cells were cultured on fibrinogen, though cells cultured on collagen types | or IV were resistant to the antiproliferative activity of HK.
Example 2
Apoptosis of Endothelial Cells Induced by
Two-Chain High Molecular Weight Kininogen
A. Experimental
Induction of endothelial cell apoptosis after exposure of cells to HK, was determined using three assays.
Cells plated on glass coverslips were cultured in the absence or presence of 30 nM HK, for periods of 2-24 hours. Cells were then fixed for 1 hourin phosphate-buffered saline (PBS) containing 1% formaldehyde, and stained for 2 hours with a solution containing 1 pg/ml of 4',6'-diamidino- 2-phenylindole dihydrochloride (DAPI) and 10 ug/ml of sulforhodamine 101 . (Molecular Probes, Eugene OR). Stained cells were visualized by UV illumination using a Nikon Microphot FXA microscope (objective 40X,
Neofluor). Nuclear condensation, fragmentation and hyperchromaticity were considered to reflect apoptosis. oo
DNA fragmentation after exposure of cells to HK, was also directly assessed. Briefly, cells were cultured in the absence or presence of 30 NM HK, , for varying periods, and DNA isolated following cel! lysis in a buffer containing 20 mm Tris-HC1, pH 7.4, 5 mM ethylenediamine tetraacetic acid (EDTA) and 0.4% Triton X-100. After centrifugation to remove nuclei and insoluble material, the supernatant was extracted with an equal volume of phenal:chloroform: 1-isopropanol (25:24:1), and DNA precipitated by the addition of 50 pl of 4 M LiCl and 500 pt 2-propanol.
Precipitated DNA was dried using a Speed-Vac (Savant, Holbrook, NY),
7 WO 00/27866 PCT/US99/26419 resuspended in 20 mM Tris-HC1, pH 7.4, containing 5 mM EDTA and incubated for 30 minutes in the presence of 0.1 mg/ml RNase A. Samples were then analyzed by 0.8% agarose gel electrophoresis and visualized under UV light after staining with ethidium bromide.
Apoptosis was also confirmed by using the TUNEL reaction (/n Situ Cell Death Detection Kit, Boehringer Mannheim, indianapolis, IN) to label control cells and those exposed to HK, with fluorescein-conjugated dUTP, per the manufacturer's protocol. Labeled cells were then analyzed by flow cytometry.
B. Results
Staining of cells with DAPI revealed nuclear condensation and fragmentation only in cells that had been exposed to HK,; these changes were observed in 30-50% of the cells within 6 hours after HK, addition (Figure 6A). Parallel studies in which cells were incubated with
Trypan blue after incubation with HK, revealed no evidence of dye uptake, demonstrating that HK, did not induce cell lysis, and that its effects were due to the induction of apoptosis rather than cytotoxicity. Consistent with this observation, analysis of DNA isolated from cells incubated with HK, revealed striking fragmentation, which was first apparent approximately 6 hours after addition of the HK, (Figure 7A). Consistent with these results, ] a specific “laddering” pattern of DNA fragmentation, characteristic of apoptosis, was apparent upon electrophoretic analysis of DNA from cells exposed to HK, (data not shown). Finally, flow cytometric analysis of cells : incubated in the absence or presence of HK, and labeled with fluorescein dUTP by the TUNEL reaction, and revealed a rightward shift of the major peak only in cell populations exposed to HK, (not shown). As with DAPI staining and DNA fragmentation, these changes were apparent approximately 6 hours after exposure of cells to HK,. Taken together, these studies demonstrate that the antiproliferative activity of HK, reflects its ability to induce endothelial cell apoptosis. N
Example 3
Inhibition of Cytokine-Stimulated Angiogenesis by
Two-Chain High Molecular Weight Kininogen In Vivo
A. Experimental :
The effect of HK, on cytokine-stimulated angiogenesis in vivo : was determined using a previously-described assay in which the neovascularization of a Matrigel! "plug" containing bFGF is assessed (Passaniti et al., Lab Invest 67:519-528, 1992). Briefly, athymic Ner nude mice (7-8 weeks old, females) were injected subcutaneously on the left and right mid-back with 0.25 mi of chilled Matrigel containing 400 ng bFGF and 50 pg heparin, to which either 25 pl of PBS (left mid-back injection) or an equal volume of PBS containing 0.4 mg/ml HK, (right mid-back injection) had been added. Immediately after injection, the Matrigel solidified and remained as a solid, subcutaneous "plug" through the 4 day duration of the experiment. At this point, mice were sacrificed, and the skin incised along the mid back and peeled back over the flanks to expose the Matrigel plugs.
Plugs were then photographed prior to their excision, fixation and processing, as previously described (Passaniti et al., Lab Invest 67:519- : 528, 1992).
The effect of HK, on cytokine-stimulated angiogenesis in vivo was also determined using a rat corneal micropocket angiogenesis assay as previously described (Polverini ef al., Meth. Enzymol. 198:440-450, 1991: Fournier et al., Inv. Opthal. Vis. Sci. 21:354, 1981). Pellets were prepared using 12% hydron. Control pellets contained bFGF (50 ng/pellet), while test pellets contained bFGF and HK, (final concentration 10 pM). A ) single pellet was implanted in a 2 mm pocket prepared in each cornea, 1 mm from the limbus. The left eye of each animal received the control : pellet, while thé fight eye received the HK, -tohtaiting peiiel. Cuttiesi neovascularization was measured after 7 days, at which time a digitai image of each eye was obtained using a Nikon NS-1 slit lamp. To determine the total area of neovessels in each eye, digital images were analyzed using a Leica-Qwin (Northvale, NJ) image analysis system (Conrad et al., Lab. Invest. 70:434, 1994). B
B. Results Co
As depicted in Figures 8A and 8B, Matrigel plugs containing bF GF induced exuberant vessel ingrowth within 4 days after implantation.
< WO 00/27866 : PCT/US99/26419
In contrast, no neovascularization of Matrigel plugs which contained bFGF and HK, was observed (Figures 8C and 8D). In addition, these plugs remained transparent, as opposed to the opaque appearance acquired by . the plugs, suggesting that HK, blocked the intravasation of migratory cells into the Matrigel. The latter hypothesis was confirmed by histological analysis, which demonstrated markedly fewer cells within the HK_- containing Matrigel plugs. Furthermore, the cells which had migrated into these plugs appeared rounded and apoptotic, in contrast to the elongated, migratory phenotype of the cells invading the control plugs.
In the corneal micropocket angiogenesis assay, bFGF- containing hydron pellets implanted into control corneas induced a robust angiogenic response. In comparison, the length and density of neovessels were significantly reduced in corneas in which the implanted pellets contained bFGF and HK,. Computer analysis of digital images revealed that the total vessel area within corneas that received HK,-containing pellets (293,807 um?) was reduced by 82% in comparison to those in which pellets contained bFGF only (53,931 ym?) (P<0.000000005).
Example 4
Effect of Peptide Analogs of Two-Chain High Molecular
Weight Kininogen on Endothelial Cell Proliferation
The following HK -derived peptides were synthesized:
Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-
Gly-His (SEQ ID NO:7);
Gly-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-
Lys-Asn (SEQ ID NO:8); and
His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-
Lys-Thr (SEQ ID NO:9).
The endothelial cell proliferation assay of Example 1 was performed, utilizing bFGF as the growth factor to stimulate angiogenesis and 50 pM of the above peptides. The same mathematical formula was employed but proliferation in the presence of GF plus peptide substituted for proliferation in the presence of GF plus HK, The percent inhibition of endothelial cell proliferation attributable to the peptides is given in Table 1.
The value for HK, is also reported. The greater than 100% inhibition level achieved in this assay with HK, (100% being no endothelial cell proliferation, that is, the level of proliferation in medium containing 2% serum alone, without added growth factor) reflects the fact that HK, induces endothelial cell apoptosis.
Table 1
Inhibition of Endothelial Cell Proliferation by HK, and HK,-Derived
Peptides
Inhibitor (50 uM) || Inhibition of Endothelial IC 50
EE er seapwos | em | ew
All references discussed herein are incorporated by reference. One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The ) present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than tn the foregoing specification, as indicating the scope of the invention.
Claims (33)
1. Use of a substance selected from the group of two- chain kininogen, single-chain kininogen, and a compound of the formula Xi-His-Lys-X-Lys-X; wherein X is any amino acid, X4 is from zero to twelve amino acids, and . Xz is from zero to twelve amino acids, : and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group, for the manufacture of a medicament for inhibiting angiogenesis.
2. Use of a substance according to claim 1 wherein the substance is two-chain kininogen.
3. Use of a substance according to claim 1 wherein the substance is single-chain kininogen.
4. Use of a substance according to claim 1 wherein the substance is a compound of the formula X4-His-Lys-X-Lys-X;,
5. Use of a compound according to claim 4 wherein X1 is (i) zero amino acids, or (ii) the segment His-Gly-His-Glu-GIn-GIn-His- Gly-Leu-Gly-His-Gly (SEQ ID NO:1) , or N-terminal truncation fragment thereof containing at least one amino acid, and Xa is (i) zero amino acids, or Amended Sheet 16/05/2002
(il) the segment Leu-Asp-Asp-Asp-Leu-Glu- His-GIn-Gly-Gly-His-Val (SEQ ID NO:2), or C- terminal truncation fragment thereof containing at least one amino acid.
6. Use of a compound according to claim 4 wherein Xi is (i) zero amino acids, or (ii) the segment Gly-His-Lys-His-Lys-His-Gly- His-Gly-His-Gly-Lys (SEQ ID NO:3) or N-terminal truncation fragment thereof containing at least one amino acid, and Xo is (i) zero amino acids, or (i) the segment Gly-Lys-Lys-Asn-Gly-Lys- His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4), or C- terminal truncation fragment thereof containing at least one amino acid.
7. Use of a compound according to any of claims 4-6 wherein Xj is from zero to six amino acids, and : Xz is from zero to six amino acids.
8. Use of a compound according to any of claims 4-7 wherein X is selected from the group consisting of Ala, Leu, lle, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gin, Cys, and Gly.
9. Use of a compound according to claim 8 wherein X is Asn, Phe or His. Amended Sheet 16/05/2002
10. Use of a compound according to claim 5 wherein : the compound has substantial amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-GIn-GIn-His-Gly-Leu-Gly-His-Gly- His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-Gly-His-Val (SEQ ID NO:5).
11. Use of a compound according to claim 5 wherein the compound has the amino acid sequence His-Gly-His-Glu-GIn-GIn- His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu- His-GIn-Gly-Gly-His-Val (SEQ ID NO:5).
12. Use of a compound according to claim 5 wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu- Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-Gly-His(SEQ ID NO:7).
13. Use of a compound according to claim 6 wherein the compound has substantial amino acid sequence homology to the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys- His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).
14. Use of a compound according to claim 6 wherein the compound has the amino acid sequence Gly-His-Lys-His-Lys-His- Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His- Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).
15. Use of a compound according to claim 6 wherein the compound has the amino acid sequence Lys-His-Gly-His-Gly-His- Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).
16. Use of a compound according to claim 6 wherein the compound has the amino acid sequence His-Lys-Asn-Lys-Gly-Lys- Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9). Amended Sheet 16/05/2002
17. Use of a substance according to any preceding claim wherein inhibition of angiogenesis includes inhibition of endothelial cell proliferation.
18. Use of a substance according to claim 17 wherein inhibition of endothelial cell proliferation includes induction of endothelial cell apoptosis.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula X;- His-Lys-X-Lys-X, wherein X is an amino acid selected from the group consisting of Ala, Leu, lle, Val, Pro, Trp, Met, Thr, Tyr, Asn, Gin, Cys, and Gly, X1 is from zero to six amino acids, and Xa is from zero to six amino acids, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.
20. A compound of the formula X;-His-Lys-X-Lys-X; wherein X is any amino acid, Xqis the segment His-Gly-His-Glu-GIn-Gin-His- ~ Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal truncation fragment thereof containing at least one amino acid, and Xa is (i) zero amino acids, or (it) the segment Leu-Asp-Asp-Asp-Leu-Glu- His-GIn-Gly-Gly-His-Val (SEQ ID NO:2), or C- Amended Sheet 16/05/2002 terminal truncation fragment thereof containing at least one amino acid, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.
21. A compound according to claim 20 wherein X is : selected from the group consisting of Ala, Leu, lle, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gin, Cys, and Gly.
22. A compound according to claim 21 wherein X is Asn, Phe or His.
23. The compound according to claim 22 which has the amino acid sequence His-Gly-His-Glu-GIn-GlIn-His-Gly-Leu-Gly-His-Gly- His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-GIn-Gly-Gly-His-Val (SEQ ID NO:5), and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.
24. The compound according to claim 22 which has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu- His-GIn-Gly-Gly-His (SEQ ID NO:7), and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.
25. The compound having the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly- Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6), and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.
26. A compound having the amino acid sequence Lys- His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NQ:8), said compound optionally comprising an amino-terminal and/or carboxy-terminal protecting group. Amended Sheet 16/05/2002
27. A compound having the amino acid sequence His- Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9), said compound optionally comprising an amino-terminal and/or carboxy-terminal protecting group.
28. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 20-27. :
29. Use of a substance selected from the group of two- chain kininogen, single-chain kininogen, and a compound of the formula Xi-His-Lys-X-Lys-X; wherein X is any amino acid, Xj is from zero to twelve amino acids, and Xz is from zero to twelve amino acids, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group, for the manufacture of a medicament for inhibiting endothelial cell proliferation.
30. Use of a substance selected from the group of two- chain kininogen, single-chain kininogen, and a compound of the formula X4-His-Lys-X-Lys-X, wherein X is any amino acid, X1 is from zero to twelve amino acids, and : Xz is from zero to twelve amino acids, and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group, for the manufacture of a medicament for inducing endothelial cell apoptosis.
31. Use of a substance according to claim 29 or 30 wherein the substance is two-chain kininogen. Amended Sheet 16/05/2002
© WO 00/27866 PCT/US99/26419-
32. Use of a substance according to claim 29 or 30 wherein the substance is single-chain kininogen.
33. Use of a substance according to claim 29 or 30 3) wherein the substance is a compound of the formula X;-His-Lys-X-Lys-
Xa. Amended Sheet 16/05/2002
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10783398P | 1998-11-10 | 1998-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104130B true ZA200104130B (en) | 2002-05-21 |
Family
ID=22318715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104130A ZA200104130B (en) | 1998-11-10 | 2001-05-21 | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1137659A4 (en) |
JP (1) | JP2002529474A (en) |
AU (1) | AU773862B2 (en) |
CA (1) | CA2350915A1 (en) |
IL (1) | IL142822A0 (en) |
NZ (1) | NZ511618A (en) |
WO (1) | WO2000027866A1 (en) |
ZA (1) | ZA200104130B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1227842A4 (en) * | 1999-11-12 | 2005-06-08 | Univ Temple | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
AU2001277119A1 (en) * | 2000-07-24 | 2002-02-25 | Attenuon, Llc | Human kininogen d5 domain polypeptides and their use |
US7098187B2 (en) | 2002-09-13 | 2006-08-29 | Attenuon, Llc | Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent |
SE0301431D0 (en) | 2003-05-19 | 2003-05-19 | Dermagen | Novel antimicrobial peptides |
GB0821721D0 (en) * | 2008-11-27 | 2008-12-31 | Hansa Medical Ab | Antimicrobial therapy |
CN104155457B (en) * | 2014-08-22 | 2016-11-16 | 北京蛋白质组研究中心 | Relevant " the box-like mark of the polypeptide-protein groups " detection kit of a kind of colorectal cancer |
CN104211807B (en) * | 2014-08-22 | 2017-10-20 | 北京蛋白质组研究中心 | It is a kind of to resist monoclonal antibody of two kinds of polypeptides and its preparation method and application |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5596079A (en) * | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
JPH0782172A (en) * | 1993-09-17 | 1995-03-28 | Hoechst Japan Ltd | Wound healing agent |
CA2189340A1 (en) * | 1994-05-04 | 1995-11-16 | James W. Dennis | Modulators of cytokines of the tgf-.beta. superfamily and methods for assaying for same |
JPH08208692A (en) * | 1994-09-28 | 1996-08-13 | Sumitomo Pharmaceut Co Ltd | New cell adhesion inhibiting peptide derivative |
EP0808627A2 (en) * | 1996-05-22 | 1997-11-26 | Hoechst Aktiengesellschaft | Use of non-peptide bradykinin antagonists for treating and preventing chronic fibrogenetic liver diseases, acute liver diseases and complications thereof |
CA2187728A1 (en) * | 1996-05-29 | 1997-11-29 | Mary Lou Guerinot | Iron-regulated metal transporters and uses therefor |
-
1999
- 1999-11-05 AU AU19106/00A patent/AU773862B2/en not_active Ceased
- 1999-11-05 NZ NZ511618A patent/NZ511618A/en unknown
- 1999-11-05 EP EP99962723A patent/EP1137659A4/en not_active Withdrawn
- 1999-11-05 WO PCT/US1999/026419 patent/WO2000027866A1/en not_active Application Discontinuation
- 1999-11-05 JP JP2000581043A patent/JP2002529474A/en not_active Withdrawn
- 1999-11-05 IL IL14282299A patent/IL142822A0/en unknown
- 1999-11-05 CA CA002350915A patent/CA2350915A1/en not_active Abandoned
-
2001
- 2001-05-21 ZA ZA200104130A patent/ZA200104130B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000027866A1 (en) | 2000-05-18 |
AU1910600A (en) | 2000-05-29 |
IL142822A0 (en) | 2002-03-10 |
JP2002529474A (en) | 2002-09-10 |
EP1137659A1 (en) | 2001-10-04 |
CA2350915A1 (en) | 2000-05-18 |
EP1137659A4 (en) | 2005-08-10 |
AU773862B2 (en) | 2004-06-10 |
NZ511618A (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3789931B2 (en) | Peptide inhibitors of fibronectin and related collagen-binding proteins | |
RU2156468C2 (en) | Method of assay of presence or absence of inhibitory activity of platelet aggregation (pa1), purified and isolated inhibitor of platelet activity (pa1) and/or its truncated form, method of purification of pa1 from snake venom, pharmaceutical composition for prevention of thrombus formation, method of inhibition of thrombus formation | |
CA2329250C (en) | Peptide antiangiogenic drugs | |
US6638912B2 (en) | Peptide compositions mimicking TGF-β activity | |
JPH10502349A (en) | Method for inhibiting the binding of integrin α 4 and β 1 to VCAM-1 or fibronectin | |
WO2003018758A2 (en) | Reagents and methods for smooth muscle therapies | |
CA2052022A1 (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
AU773862B2 (en) | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof | |
EP0514721B1 (en) | Peptides having thrombospondin-like activity and their therapeutic use | |
EP0639202B1 (en) | Stable polypeptide composition | |
US6284726B1 (en) | Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5 | |
US6339062B1 (en) | Retroinverso polypeptides that mimic or inhibit thrombospondin activity | |
JPH08208692A (en) | New cell adhesion inhibiting peptide derivative | |
US6869931B1 (en) | Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs | |
US6767889B1 (en) | Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof | |
AU774694B2 (en) | Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs | |
AU2002324777C1 (en) | Reagents and methods for smooth muscle therapies | |
JPH07278191A (en) | New peptide or protein and method for searching the same | |
AU2002324777A1 (en) | Reagents and methods for smooth muscle therapies |